Your browser doesn't support javascript.
loading
Neocarzilin A Is a Potent Inhibitor of Cancer Cell Motility Targeting VAT-1 Controlled Pathways.
Gleissner, Carolin M-L; Pyka, Carolin L; Heydenreuter, Wolfgang; Gronauer, Thomas F; Atzberger, Carina; Korotkov, Vadim S; Cheng, Weiting; Hacker, Stephan M; Vollmar, Angelika M; Braig, Simone; Sieber, Stephan A.
Afiliação
  • Gleissner CM; Center for Integrated Protein Science at the Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, Garching, D-85747, Germany.
  • Pyka CL; Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University of Munich (LMU), Butenandtstrasse 5-13, Munich, D-81377, Germany.
  • Heydenreuter W; Center for Integrated Protein Science at the Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, Garching, D-85747, Germany.
  • Gronauer TF; Center for Integrated Protein Science at the Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, Garching, D-85747, Germany.
  • Atzberger C; Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University of Munich (LMU), Butenandtstrasse 5-13, Munich, D-81377, Germany.
  • Korotkov VS; Center for Integrated Protein Science at the Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, Garching, D-85747, Germany.
  • Cheng W; Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University of Munich (LMU), Butenandtstrasse 5-13, Munich, D-81377, Germany.
  • Hacker SM; Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, Garching, D-85747, Germany.
  • Vollmar AM; Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University of Munich (LMU), Butenandtstrasse 5-13, Munich, D-81377, Germany.
  • Braig S; Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University of Munich (LMU), Butenandtstrasse 5-13, Munich, D-81377, Germany.
  • Sieber SA; Center for Integrated Protein Science at the Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, Garching, D-85747, Germany.
ACS Cent Sci ; 5(7): 1170-1178, 2019 Jul 24.
Article em En | MEDLINE | ID: mdl-31403069
ABSTRACT
The natural product neocarzilin A (NCA) was discovered decades ago, and despite its potent cytotoxic effects no mode of action studies have been performed up to date. Synthesis of neocarzilins A, B, and C and a stereoisomer of NCA provided insights into structural preferences as well as access to probes for functional studies. NCA turned out to be the most active member and was not only effective against cell proliferation but also migration, a novel and so far overlooked activity. To decipher the molecular mode of action, we applied chemical proteomics for target discovery and revealed that NCA targets cancer cell migration via irreversible binding to the largely uncharacterized synaptic vesicle membrane protein VAT-1. A corresponding knockout of the protein confirmed the phenotype, and pull-down studies showed the interaction with an intricate network of key migration mediators such as Talin-1. Overall, we introduce VAT-1 as a promising novel target for the development of selective migration inhibitors with the perspective to limit toxicity in the absence of antiproliferative effects.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article